systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-99Research ArticleКАРДИОЛОГИЯCARDIOLOGYΒ-АДРЕНОБЛОКАТОРЫ: МЕСТО ИХ ПРИМЕНЕНИЯ ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ В СОВРЕМЕННЫХ УСЛОВИЯХЧазоваИ. Е.noemail@neicon.ruФГУ Российский кардиологический научно-производственный комплекс Росмедтехнологий, МоскваRussian Federation2007231220224247Copyright © Чазова И.Е., 20222022Чазова И.Е.Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/99

Β–Адреноблокаторы (БАБ), по данным многочисленных зарубежных и российских исследований, относятся к одному из основных антигипертензивных классов лекарственных препаратов.Тем не менее более широкому применению БАБ препятствуют побочные эффекты, которые они могут вызывать.Следует отметить, что большинство из описанных побочных эффектов чаще встречается при назначении неселективных или малоселективных БАБ, утрачивающих или снижающих ее при назначении в больших дозах. В последние годы все большее распространение в повседневной клинической практике получают более современные представители класса БАБ. Одним из них является метопролола сукцинат в форме замедленного высвобождения – Беталок ЗОК. Эта лекарственная форма представляет собой таблетку, разработанную на основании высоких фармацевтических технологий.

ReferencesBradley H.A, Wiysonge C.S, Volmink J.A et al. How strong is the evi dence for use of beta - blockers as first - line therapy for hypertension? Systematic review and meta - analysis. J Hypertens 2006; 24:2131–41Bradley H.A, Wiysonge C.S, Volmink J.A et al. How strong is the evi dence for use of beta - blockers as first - line therapy for hypertension? Systematic review and meta - analysis. J Hypertens 2006; 24:2131–41Lindholm L.H, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta - analysis. Lancet 2005; 366:1545–53Lindholm L.H, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta - analysis. Lancet 2005; 366:1545–53Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbid ity and mortality in the Losartan Intervention For Endpoint reduc tion in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–03Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbid ity and mortality in the Losartan Intervention For Endpoint reduc tion in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–03Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre ran domized controlled trial. Lancet 2005; 366:895–906Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre ran domized controlled trial. Lancet 2005; 366:895–906Guidelines for the Management of Hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiol ogy (ESC). J. Hypertension 2007; 25:1105–87Guidelines for the Management of Hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiol ogy (ESC). J. Hypertension 2007; 25:1105–87Sandberg A, Abrahamsson B, Reg_rdh C.G et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with meto prolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30:2–16Sandberg A, Abrahamsson B, Reg_rdh C.G et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with meto prolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30:2–16Omvik P, Leer J, Istad H, Westergren G. Equal Efficacy and Improved Tolerability with 50 mg Controlled - Release Metoprolol Compared with 100 mg Conventional Metoprolol in Hypertensive Patients. Am J Ther 1994; 1:65–73Omvik P, Leer J, Istad H, Westergren G. Equal Efficacy and Improved Tolerability with 50 mg Controlled - Release Metoprolol Compared with 100 mg Conventional Metoprolol in Hypertensive Patients. Am J Ther 1994; 1:65–73Lofdahl C.G, Dahl_f C, Westergren G et al. Controlled - release meto prolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol 1988, 33:25–32Lofdahl C.G, Dahl_f C, Westergren G et al. Controlled - release meto prolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol 1988, 33:25–32Kendall M, Akhlaghi S, Hughes B, Lewis H. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? J Clin Pharmacol 1990, 30:98–102Kendall M, Akhlaghi S, Hughes B, Lewis H. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? J Clin Pharmacol 1990, 30:98–102Kerr D, Mac Donald I.A, Heller S.R, Tattersall R.B. Beta - adrenocep tor blockade and hypoglycaemia. A randomised, double - blind, placebo controlled comparison of metoprolol CR, atenolol and pro pranolol LA in normal subjects. Br J Clin Pharmacol. 1990; 29(6):685–93Kerr D, Mac Donald I.A, Heller S.R, Tattersall R.B. Beta - adrenocep tor blockade and hypoglycaemia. A randomised, double - blind, placebo controlled comparison of metoprolol CR, atenolol and pro pranolol LA in normal subjects. Br J Clin Pharmacol. 1990; 29(6):685–93Benfield P, Clissold S.P, Brogden R.N. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs. 1986; 31(5):376–429Benfield P, Clissold S.P, Brogden R.N. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs. 1986; 31(5):376–429Wiklund O Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima - media thickness in patients with hypercholesterolemia: a 3-year random ized study. Stroke 2002; 33:572–7Wiklund O Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima - media thickness in patients with hypercholesterolemia: a 3-year random ized study. Stroke 2002; 33:572–7Hedblad B, Wikstrand J, Janzon L et al. Low - dose metoprolol CR/XL and fluvastatin slow progression of carotid intima - media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).Circulation 2001; 103:1721–6Hedblad B, Wikstrand J, Janzon L et al. Low - dose metoprolol CR/XL and fluvastatin slow progression of carotid intima - media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).Circulation 2001; 103:1721–6

The authors declare that there are no conflicts of interest present.